-
ELCC Co-Chair, Professor Enrico Ruffini Highlights Key Differences in Surgical Management Strategies for Thymoma and Thymic Carcinoma
At the 2025 European Lung Cancer Congress (ELCC), Professor Enrico Ruffini, thoracic surgeon at the Università di Torino and Co-Chair of the ELCC, delivered a dedicated presentation titled “Thymoma and thymic carcinoma: Different surgical management strategies?” During the conference, Oncology Frontier had the opportunity to speak with Professor Ruffini for an in-depth discussion on the…
-
Darolutamide and PSA Response: New Insights from ARANOTE at EAU25
Presented at the 40th Annual EAU Congress, the ARANOTE study offered valuable post hoc insights into the significance of PSA response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated…
-
Professor Qingguo Li : Advancing Minimally Invasive Techniques to Preserve Function and the Anus in Low Rectal Cancer
Oncology Frontier: At this year’s meeting, you gave an excellent presentation on the development of an expert consensus for the prevention and management of Low Anterior Resection Syndrome (LARS) in…
-
Professor Xue Yang: ADC Research Updates from the 2025 ELCC Conference
Oncology Frontier：What new ADC data were presented at the 2025 ELCC in the field of first-line and later-line lung cancer treatment? Professor Xue Yang:：In the field of later-line treatment, one…
-
Post-ASCO GI 2025 | Professors Kefeng Ding and Ying Yuan Discuss the BBCAPX Study: A New Path Forward in Immunotherapy for RAS-Mutant/MSS Unresectable
Following the presentation, Professor Kefeng Ding joined Professor Yuan in a dialogue reflecting on the key progress of the study and its future direction, rekindling hope for immunotherapy in this…
-
Prof. Chunfang Hao: Highlights from the Updated CSCO Guidelines for HR+ mBC – A Dual Emphasis on Endocrine Combination Therapy and Precision Testing
The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, featured the highly anticipated update to the CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer (CSCO BC Guidelines). The latest edition further refines stratified treatment strategies and emphasizes the importance of both precision medicine and combination therapies—providing more detailed…
-
In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout
As the 2025 Annual Meeting of the National Comprehensive Cancer Network (NCCN) concluded, Oncology Frontier exclusively interviewed Dr. Wui-Jin Koh, Chief Medical Officer of NCCN, to decode the future trends in cancer care. From the application prospects of AI-assisted medical decision-making to the inclusive practice of decentralized clinical trials, from the systemic challenges of combating…
-
ELCC 2025 | Professor Wenxiu Yao Shares Insights on the Latest Advances in ADC Therapy for Lung Cancer
At the 2024 European Lung Cancer Congress (ELCC) held in Paris, Oncology Frontier conducted an exclusive interview with Professor Wenxiu Yao from Sichuan Cancer Hospital. Professor Yao provided in-depth commentary on the latest research presented at the congress regarding antibody-drug conjugates (ADCs) in the treatment of lung cancer.
Connecting Medical Expertise through Media